Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Fiscal Year End: April 1, 2006
Business Overview: Haemonetics is a market leader in developing and manufacturing automated systems and single-use consumables for blood donation, blood processing, and surgical salvage. The company operates as a single segment focused on automated blood processing systems, serving two primary customer families: blood donors (plasma, platelet, and red cell collection) and surgical patients (blood salvage). Operations are global, with significant revenue generated in the U.S., Europe, and Japan.
Key Financial Metrics (Fiscal Year 2006)
| Metric | 2006 | 2005 | 2004 |
|---|---|---|---|
| Net Revenues | $419.7 million | $383.6 million | $364.2 million |
| Gross Profit | $220.5 million | $197.9 million | $173.5 million |
| Gross Margin | 52.5% | 51.6% | 47.6% |
| Operating Income | $99.0 million | $59.8 million | $47.3 million |
| Net Income | $69.1 million | $39.6 million | $29.3 million |
| Diluted EPS | $2.51 | $1.52 | $1.19 |
| Cash & Equivalents | $250.7 million | $185.8 million | $79.5 million |
| Total Debt | $39.2 million | $45.8 million | $58.3 million |
| Working Capital | $330.3 million | $255.7 million | $185.6 million |
| Current Ratio | 4.7 | 3.9 | 2.9 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 9.4% year-over-year, driven by a 7.0% increase in disposable product sales (87.4% of total revenue) and a 24.5% increase in equipment sales. Growth was supported by unit increases in plasma and red cell lines and favorable foreign exchange effects (0.5%).
- Profitability Surge: Operating income jumped 65.5% and Net Income rose 74.3%. A significant portion of this increase was due to a $26.4 million arbitration award income recorded in Q3 2006 from Baxter International, related to a dispute over supply contracts assumed after Baxter acquired Alpha Therapeutic Corporation.
- Excluding Arbitration: Without the arbitration award and foreign exchange benefits, operating income would have increased by only 5.8% over 2005.
- Expense Increases: Research and Development (R&D) expenses rose 32.6% to $26.5 million, driven by new product development (cardioPAT, Cymbal) and a $3.8 million impairment charge for a platelet pathogen reduction intangible asset.
- Geographic Mix: International sales accounted for 61.5% of total revenue, with Japan representing 18.0% of total net revenues.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The $26.4 million arbitration award is a non-recurring item. Additionally, the company recorded a $3.8 million impairment charge for intangible assets related to pathogen reduction technology.
- Outlook & Strategy: Management remains focused on increasing sales of red cell collection technology and orthopedic surgical blood salvage systems. The company is introducing new products, including the cardioPAT system and the Cymbal red cell collector. They expect to continue investing in R&D.
- Acquisition: On June 6, 2006 (post-fiscal year end), Haemonetics entered into a definitive agreement to acquire the remaining shares of Arryx, Inc. for $26 million in cash.
- Risks:
- Customer Concentration: Sales to the Japanese Red Cross Society accounted for 18.0% of net revenues in 2006.
- Foreign Exchange: Approximately 61% of sales are in foreign currencies (primarily Euro and Yen), exposing the company to currency fluctuation risks.
- Regulatory: Products are subject to strict FDA and international regulations; delays in approvals or changes in standards could impact operations.
- Competition: Competitors include Baxter International, Gambro BCT, Medtronic, and Fresenius.
Key Facts for Investor Verification
- Arbitration Impact: Verify the sustainability of earnings growth by excluding the one-time $26.4 million Baxter arbitration award from operating income.
- Customer Concentration: Assess the risk associated with the Japanese Red Cross Society representing 18% of total revenue.
- Intangible Asset Impairment: Review the $3.8 million impairment charge related to pathogen reduction technology and the status of the ongoing arbitration with Baxter regarding this specific agreement.
- Foreign Exchange Sensitivity: Monitor the impact of the U.S. dollar strength against the Euro and Yen on future reported revenues and margins.
- Acquisition Integration: Track the financial impact and integration progress of the Arryx, Inc. acquisition announced in June 2006.